• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    H.C. Wainwright initiated coverage on Vanda Pharma with a new price target

    10/31/24 6:31:19 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $VNDA alert in real time by email
    H.C. Wainwright initiated coverage of Vanda Pharma with a rating of Buy and set a new price target of $18.00
    Get the next $VNDA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VNDA

    DatePrice TargetRatingAnalyst
    10/31/2024$18.00Buy
    H.C. Wainwright
    7/11/2024$11.00Overweight
    Cantor Fitzgerald
    2/25/2022$24.00 → $12.00Buy → Hold
    Jefferies
    More analyst ratings

    $VNDA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for PONVORY issued to VANDA PHARMS INC

      Submission status for VANDA PHARMS INC's drug PONVORY (SUPPL-6) with active ingredient PONESIMOD has changed to 'Approval' on 06/05/2024. Application Category: NDA, Application Number: 213498, Application Classification: Labeling

      6/17/24 12:07:18 AM ET
      $VNDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for PONVORY issued to VANDA PHARMS INC

      Submission status for VANDA PHARMS INC's drug PONVORY (SUPPL-5) with active ingredient PONESIMOD has changed to 'Approval' on 06/05/2024. Application Category: NDA, Application Number: 213498, Application Classification: Labeling

      6/17/24 12:07:18 AM ET
      $VNDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for FANAPT issued to VANDA PHARMS INC

      Submission status for VANDA PHARMS INC's drug FANAPT (SUPPL-23) with active ingredient ILOPERIDONE has changed to 'Approval' on 04/02/2024. Application Category: NDA, Application Number: 022192, Application Classification: Efficacy

      4/3/24 4:12:36 PM ET
      $VNDA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VNDA
    Leadership Updates

    Live Leadership Updates

    See more
    • Vanda Pharmaceuticals Appoints Dr. Tage Honoré to its Board of Directors

      WASHINGTON, March 17, 2023 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced the appointment of Tage Honoré, Ph.D., D.Sc. to its Board of Directors effective March 15, 2023. Following Dr. Honoré's appointment, Vanda's Board of Directors is now comprised of six directors, five of whom are independent. "Tage is a highly accomplished industry leader and respected scientist with deep experience across a diverse range of therapeutic areas," said Mihael H. Polymeropoulos, M.D., Vanda's President, CEO and Chairman of the Board. "We are confident that his scientific expertise and executive experience will be invaluable, and look forward to working with him as we contin

      3/17/23 7:00:00 AM ET
      $VNDA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VNDA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Mitchell Stephen Ray sold $32,130 worth of shares (7,000 units at $4.59), decreasing direct ownership by 7% to 97,082 units (SEC Form 4)

      4 - Vanda Pharmaceuticals Inc. (0001347178) (Issuer)

      6/16/25 9:10:04 PM ET
      $VNDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Mitchell Stephen Ray was granted 59,225 shares, increasing direct ownership by 132% to 104,082 units (SEC Form 4)

      4 - Vanda Pharmaceuticals Inc. (0001347178) (Issuer)

      6/9/25 5:36:16 PM ET
      $VNDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Chrousos Phaedra was granted 59,225 shares, increasing direct ownership by 92% to 123,350 units (SEC Form 4)

      4 - Vanda Pharmaceuticals Inc. (0001347178) (Issuer)

      6/9/25 5:35:49 PM ET
      $VNDA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VNDA
    SEC Filings

    See more
    • SEC Form 144 filed by Vanda Pharmaceuticals Inc.

      144 - Vanda Pharmaceuticals Inc. (0001347178) (Subject)

      6/13/25 9:40:59 PM ET
      $VNDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 filed by Vanda Pharmaceuticals Inc.

      S-8 - Vanda Pharmaceuticals Inc. (0001347178) (Filer)

      6/5/25 4:46:16 PM ET
      $VNDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vanda Pharmaceuticals Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Vanda Pharmaceuticals Inc. (0001347178) (Filer)

      6/5/25 4:32:45 PM ET
      $VNDA
      Biotechnology: Pharmaceutical Preparations
      Health Care